Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GMP Warnings Reflect Firms’ Lack Of Commitment – Fabricant

This article was originally published in The Tan Sheet

Executive Summary

FDA inspectors continue to find good manufacturing practice violations of a basic, rather than technical, nature. The director of the agency’s Division of Dietary Supplement Programs hammered the point home to an industry audience May 2.

You may also be interested in...



Sunset Natural Injunction Continues Rise In DoJ Supplement GMP Complaints

After litigating six civil complaints in 2014, DoJ’s uptick in bringing criminal and civil cases concerning supplement GMP violations in 2015 comes with the industry’s Senate champions, Orrin Hatch, R-Utah, and Martin Heinrich, D-NM, urging prosecutions against marketers of spiked products.

Sunset Natural Injunction Continues Rise In DoJ Supplement GMP Complaints

After litigating six civil complaints in 2014, DoJ’s uptick in bringing criminal and civil cases concerning supplement GMP violations in 2015 comes with the industry’s Senate champions, Orrin Hatch, R-Utah, and Martin Heinrich, D-NM, urging prosecutions against marketers of spiked products.

ForMor Challenges FDA On Own-Label Supplement GMP Stance

ForMor contests a warning letter from FDA stating that as an own-label distributor, the firm is subject to both packager and labeler GMP requirements. The firm says it is only a “holder” of finished products and FDA bases its warning on the GMP rule preamble, not the actual rule.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel